Navigation Links
Cempra, Inc. Reports First Quarter 2013 Financial and Operating Results
Date:4/25/2013

CHAPEL HILL, N.C., April 25, 2013 /PRNewswire/ -- Cempra, Inc. (Nasdaq: CEMP), a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases, today reported financial results for the first quarter ended March 31, 2013. The company will host a conference call and webcast at 4:30 p.m. EDT, today.

"The first quarter of 2013 was an important one for Cempra as we continued our oral solithromycin Phase 3 clinical trial in patients with community-acquired bacterial pneumonia and our Taksta Phase 2 trial in patients with prosthetic joint infections," said Prabhavathi Fernandes , Ph.D., chief executive officer of Cempra.  "Looking ahead, we continue to prepare to initiate the solithromycin intravenous-to-oral Phase 3 trial in community-acquired bacterial pneumonia, or CABP, pending available resources, and to plan meetings with the FDA on the solithromycin IV-to-oral Phase 3 trial in the second quarter and the Taksta prosthetic joint infection program later this year."

Financial ResultsQuarter ended March 31, 2013 compared to quarter ended March 31, 2012For the quarter ended March 31, 2013, Cempra reported a net loss of $10.3 million, or $0.42 per share, compared to a net loss of $3.5 million, or $0.26 per share, for the same period in 2012. 

Research and development expense in the quarter ended March 31, 2013, was $7.4 million, an increase of 293% compared to the same quarter in 2012. The higher R&D expense was primarily due to the initiation of the oral solithromycin Phase 3 clinical trial in patients with community-acquired bacterial pnuemonia and the initiation of the Taksta™ Phase 2 clinical trial in patients with prosthetic joint infections; both of which were initiated during the fourth quarter of 2012.  General and administrative expense was $2.7 million, a 172% increase compared to the quarter ended March 31, 2012, driven primarily by increased stock compensation expense and professional fees.  

First Quarter and early second quarter 2013 Highlights

  • Filed an S-3 shelf registration statement with the Securities and Exchange Commission
  • Submitted our request for an end-of-phase 2 meeting on solithromycin to the FDA
  • Clinical program updateThe company is primarily focused on the development of its two lead clinical-stage antibiotic candidates, the fluoroketolide, solithromycin, and Taksta™, the oral antibiotic being developed for staphylococcal infections.  The company expects the following events to occur during 2013:

    Solithromycin

  • 2Q13: End of Phase 2 meeting with the FDA
  • 2H13: Initiation of the IV-to-oral Phase 3 clinical trial in CABP, subject to available resources
  • 2Q13: Present the ongoing Phase 2 gonococcus clinical study at ECCMID
  • Taksta

  • 4Q13: Top-line results of the Phase 2 trial in PJI patients
  • Financial GuidanceCempra expects its research and development expense to increase due to the initiation of clinical trials during the fourth quarter of 2012.  The company's cash and equivalents are expected to be sufficient to fund current operations into 2015.  This projection does not include any funds for the initiation of the solithromycin IV-to-oral Phase 3 clinical trial in CABP.

    Conference Call and WebcastThe conference call may be accessed by dialing 877-377-7553 for domestic callers and 253-237-1151 for international callers. Please specify to the operator that you would like to join the "Cempra, Inc., First Quarter 2013 Financial Results Call, conference ID#: 33311244." The conference call will be webcast live under the investor relations section of Cempra's website at www.cempra.com, and will be archived there for 30 days following the call. Please visit Cempra's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

    About Cempra, Inc.Founded in 2006, Cempra, Inc. is a clinical-stage pharmaceutical company focused on developing antibiotics to meet critical medical needs in the treatment of bacterial infectious diseases. Cempra's two lead product candidates are in advanced clinical development; solithromycin in Phase 3 for CABP and TAKSTA™ (CEM-102) in Phase 2 for prosthetic joint infections. Both seek to address the need for new treatments targeting drug-resistant bacterial infections in the hospital and in the community. The company also intends to utilize its series of proprietary lead compounds from its novel macrolide library for uses such as the treatment of chronic inflammatory diseases, endocrine diseases and gastric motility disorders. Additional information about Cempra can be found at www.cempra.com.

    Please Note: This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others:  the costs, timing, regulatory review and results of our studies and clinical trials; our need to obtain additional funding and our ability to obtain future funding on acceptable terms; our ability to obtain FDA approval of our product candidates; our dependence on the success of solithromycin and Taksta; our anticipated capital expenditures and our estimates regarding our capital requirements; the possible impairment of, or inability to obtain, intellectual property rights and the costs of obtaining such rights from third parties; the unpredictability of the size of the markets for, and market acceptance of, any of our products, including solithromycin and Taksta; our ability to produce and sell any approved products and the price we are able realize for those products; our ability to retain and hire necessary employees and to staff our operations appropriately; our ability to compete in our industry; innovation by our competitors; and our ability to stay abreast of and comply with new or modified laws and regulations that currently apply or become applicable to our business.  The reader is referred to the documents that we file from time to time with the Securities and Exchange Commission.

    CEMPRA, INC.SELECTED FINANCIAL INFORMATIONCondensed Consolidated Balance Sheets(in thousands)March 31,

    December 31, 20132012ASSETS

    (unaudited)Current assetsCash and equivalents

    $ 60,152

    $ 70,109Prepaid expenses

    644

    265Total current assets

    60,796

    70,374Furniture, fixtures and equipment, net

    56

    43Deposits

    321

    321Total assets

    $ 61,173

    $ 70,738LIABILITIESCurrent liabilitiesAccounts payable

    $ 1,608

    $ 2,172Accrued expenses

    999

    342Accrued payroll and benefits

    212

    604Current portion of long-term debt

    3,008

    2,227
    Total current liabilities

    5,827

    5,345Long-term debt

    6,930

    7,623Total liabilities

    $ 12,757

    $ 12,968Commitments and contingenciesShareholders' Equity

    Common stock; $.001 par value; 80,000,000 shares authorized and 24,903,774 shares issued and outstanding at December 31, 2012 and March 31, 2013

    25

    25Addition paid-in capital

    179,961

    178,971Accumulated deficit during the development stage

    (131,570)

    (121,226)Total shareholders' equity

    48,416

    57,770Total liabilities and shareholders' equity

    $ 61,173

    $ 70,738Condensed Consolidated Statements of Operations(unaudited; in thousands, except loss per share data)Three Months Ended March 312013

    2012Revenues

    $ -

    $ -Operating expensesResearch and development

    7,371

    1,876General and administrative

    2,647

    972
    Total operating expenses

    10,018

    2,848Loss from operations

    (10,018)

    (2,848)Other income (expense), net

    (327)

    (301)Net loss and comprehensive loss

    (10,345)

    (3,149)Accretion of redeemable convertible preferred shares

    -

    (314)Net loss attributable to common shareholders

    $ (10,345)

    $ (3,463)Basic and diluted loss per share

    $ (0.42)

    $ (0.26)Basic and diluted weighted average shares outstanding

    24,904

    13,251Investor and Media Contacts:
    Robert E. Flamm , Ph.D.
    Russo Partners, LLC
    (212) 845-4226
    Robert.flamm@russopartnersllc.com

    Andreas Marathovouniotis
    Russo Partners, LLC
    (212) 845-4235
    Andreas.marathis@russopartnersllc.com

     

     

     


    '/>"/>
    SOURCE Cempra, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Cempra, Inc. to Present at 12th Annual Needham Healthcare Conference
    2. Cempra, Inc. to Report First Quarter 2013 Financial and Operating Results, and Host Conference Call and Webcast on April 25, 2013
    3. Cempra, Inc. to Present at Cowen and Company 33rd Annual Health Care Conference
    4. Cempra, Inc. to Report Fourth Quarter and Full Year 2012 Financial and Operating Results, and Host Conference Call and Webcast on February 28, 2013
    5. Cempra, Inc. to Present at Oppenheimer 23rd Annual Healthcare Conference
    6. Cempra, Inc. to Present at the Jefferies 2012 Global Healthcare Conference in London
    7. Cempra, Inc. to Report Third Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on November 8, 2012
    8. Cempra, Inc., to Present at 2012 Stifel Nicolaus Healthcare Conference and NewsMakers in the Biotech Industry Conference
    9. Cempra, Inc. Reports Second Quarter 2012 Financial and Operating Results
    10. Cempra, Inc. to Present at the NIAID Workshop Bridging the Gap - Overcoming Bottlenecks in the Development of Therapeutics for Infectious Diseases
    11. Cempra, Inc. to Report Second Quarter 2012 Financial and Operating Results, and Host Conference Call and Webcast on August 8, 2012
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/12/2017)... AVACEN Medical , Inc. (AVACEN) announced that Frost & ... Innovation Award for Its fibromyalgia pain management device. The ... market research by Frost & Sullivan,s industry experts. ... product, the AVACEN 100, offers a safe and effective solution ... ...
    (Date:10/11/2017)... Oct. 11, 2017  True Health, a leader ... its effort during National Breast Cancer Awareness month ... risks. Research ... calculated that more than 10 million American women ... in BRCA1 or BRCA2 and have not had testing. ...
    (Date:10/5/2017)...  In response to the nationwide opioid epidemic, ... (AAOMS) released prescribing recommendations that urge ibuprofen – ... a first-line therapy to manage a patient,s acute ... Recognizing the value and importance of the ... Acute and Postoperative Pain Management" stresses that practitioners ...
    Breaking Medicine Technology:
    (Date:10/12/2017)... ... ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s premier ... of the shoulder pad. The shoulder pad provides optimal support and full contact ... using cold therapy. By utilizing ice and water that is circulated from an insulated ...
    (Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
    (Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at ... D.C., for the 49th Congress of the International Society of Paediatric Oncology ... the Center for Cancer and Blood Disorders at Children’s National, and Stephen ...
    (Date:10/12/2017)... ... 2017 , ... Health Literacy Innovations (HLI), creator of the ... the Cancer Patient Education Network (CPEN), an independent professional organization that shares best ... alliance. , As CPEN’s strategic partner, HLI will help support CPEN members ...
    (Date:10/12/2017)... ... October 12, 2017 , ... Farm ... California Berkeley, and other leading institutions in announcing the launch of the ... change the way animals are raised for food. , Founding members of the ...
    Breaking Medicine News(10 mins):